The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II trial of continuous dosing of regorafenib in patients with metastatic or recurrent gastrointestinal stromal tumors (GISTs) after failure of imatinib and sunitinib.
 
Yoon-Koo Kang
Consulting or Advisory Role - Bristol-Myers Squibb; DAEHWA Pharmaceutical; Lilly/ImClone; Merck Serono; Ono Pharmaceutical; Roche/Genentech; Taiho Pharmaceutical
Research Funding - DAEHWA Pharmaceutical; LSK Biopharma
 
Jae-Joon Kim
No Relationships to Disclose
 
Changhoon Yoo
Honoraria - Bayer; Ipsen
Consulting or Advisory Role - LSK BioPharma
Speakers' Bureau - Bayer; Celgene; Ipsen
 
Mo Youl Beck
No Relationships to Disclose
 
Jungeun Ma
No Relationships to Disclose
 
Min-Hee Ryu
Honoraria - Bristol-Myers Squibb; DAEHWA Pharmaceutical; Lilly; Ono Pharmaceutical
Consulting or Advisory Role - Bristol-Myers Squibb; DAEHWA Pharmaceutical; Lilly; Ono Pharmaceutical